Wed.May 15, 2024

article thumbnail

With new partnership, Galapagos takes decentralized CAR-T manufacturing quest nationwide

Fierce Pharma

Though Galapagos has undergone plenty of staff shakeups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following | Galapagos has teamed up with the largest blood supply network in the U.S. to help establish decentralized CAR-T production on a national scale.

article thumbnail

Telehealth Is Far From Dead, Says Providence’s Virtual Care Chief

MedCity News

This year has been a messy one for virtual care companies, but that doesn’t mean that telehealth is dead, according to Eve Cunningham, Providence’s chief of virtual care and digital health. In her view, virtual care can definitely still be an important part of the care delivery model — but only if it is embedded into the greater healthcare delivery ecosystem.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

In Novo pricing probe, Sanders cranks up the heat with dire warning on projected GLP-1 spending

Fierce Pharma

After recently placing a spotlight on Novo Nordisk’s "outrageous" U.S. | A new Senate HELP Committee report says GLP-1 drugs could "bankrupt our entire health care system" because of their high prices coupled with high uptake.

262
262
article thumbnail

Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck

MedCity News

Blackstone Life Sciences startup Uniquity Bio emerged from stealth with an in-licensed drug candidate that could treat a wide range of immunology and inflammation indications. The antibody’s target puts it in competition with drugs from AstraZeneca, Pfizer, and Sanofi. The post Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck appeared first on MedCity News.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Merck KGaA's CDMO unit continues to slide but company sees an uptick coming

Fierce Pharma

Two years ago, when Merck KGaA restructured, forming a new life science business, the goal was to maximize the enticing potential of its contract development and manufacturing organization (CDMO). | On Wednesday—amid largely positive news for Merck KGaA overall—the company reported a 17% decline in sales for its CDMO unit, blaming (PDF) “unfavorable project phasing” and a streamlining of the supply chain of one of its customers.

article thumbnail

LogiPharma Europe 2024: World Courier President Talks Mitigating Supply Chain Risks

Pharmaceutical Commerce

In an interview with Pharma Commerce Editor Nicholas Saraceno at LogiPharma Europe, Nick Porter, President, World Courier discusses mitigating supply chain risks, the future of artificial intelligence in pharma logistics, and more.

Pharma 105

More Trending

article thumbnail

Wisp Begins Offering Diagnostics Through Partnership With TBD Health

MedCity News

Wisp members can now order TBD Health’s STI/STD testing kits on Wisp’s website for free delivery. The post Wisp Begins Offering Diagnostics Through Partnership With TBD Health appeared first on MedCity News.

110
110
article thumbnail

Eisai predicts sharp Leqembi sales increase as launch efforts begin to bear fruit

Fierce Pharma

Reflecting on Eisai’s Alzheimer’s disease development journey—from Aricept’s U.S. | Eisai has laid out an ambitious goal to hit 56.5 billion yen (roughly $364 million) in global Leqembi sales for the 2024 fiscal year, which wraps up next March. Eisai banked its estimate on the fact that the company and its partner Biogen have steadily improved Alzheimer’s disease diagnosis and treatment pathways over the past year.

Sales 236
article thumbnail

Ensuring sterility of a novel anti-VEGF bispecific antibody

European Pharmaceutical Review

Research has demonstrated a cost-effective storage solution for compounded faricimab kept for a maximum of 28 days. Authors of the paper stated that it provides off-label use of the anti- vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2) biologic , “while maintaining safety in the treatment of patients”. Their study compared the stability, sterility, and binding affinity to VEGF and Ang-2 of faricimab.

Safety 98
article thumbnail

When It Comes to Preventive and Proactive Wellness, Accessibility Is Key

MedCity News

Holistic care requires proactive pursuit of health services, which more people might seek if financing options are available to manage costs. The post When It Comes to Preventive and Proactive Wellness, Accessibility Is Key appeared first on MedCity News.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

GSK, UK govt put £130m into antimicrobial resistance fight

pharmaphorum

GSK has become the first founding partner of the new Fleming Initiative, which aims to tackle the rising threat of antimicrobial resistance (AMR) and is also backed by the UK government.

article thumbnail

FDA rejects label expansion for Dynavax’s hepatitis B vaccine

Pharmaceutical Technology

The US agency rejected the expanded use of Dynavax’s vaccine for adults on haemodialysis, citing insufficient efficacy and safety data.

Safety 98
article thumbnail

FDA clears Roche self-collection system for HPV screening

pharmaphorum

The FDA has approved Roche's HPV self-sampling solution that the company says can tackle unequal access to screening that can put women at risk of cervical cancer

FDA 104
article thumbnail

FDA clears IND for Verismo Therapeutics’ CAR-T therapy 

Pharmaceutical Technology

Verismo Therapeutics announced FDA clearance for a Phase I trial of its CAR-T therapy to treat non-Hodgkin lymphoma.

FDA 105
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Eisai, Biogen start delayed subcutaneous Leqembi filing

pharmaphorum

Eisai and Biogen have filed a rolling biologics license application in the US for a subcutaneous formulation of Alzheimer’s disease therapy Leqembi that was delayed by the FDA on procedural grounds.

FDA 97
article thumbnail

The Interplay Between Copyright Licensing and Exclusive Rights; AI Edition

Copyright Clearance Center

The post The Interplay Between Copyright Licensing and Exclusive Rights; AI Edition appeared first on Copyright Clearance Center.

98
article thumbnail

Home testing devices for sleep apnoea backed for NHS use

pharmaphorum

Five home-testing devices to diagnose sleep apnoea, which can affect the health of around 2.5 million adults in the UK, have been recommended for NHS use by NICE.

103
103
article thumbnail

Nabla Bio secures $26m in Series A funding round

Pharmaceutical Technology

Nabla Bio has secured $26m in a Series A financing round led by Radical Ventures, for generative protein designing.

98
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Updated BIOSECURE Act draft clears House committee

pharmaphorum

House Oversight Committee passes BIOSECURE Act, which would restrict US companies from contracting with Chinese biotechs including WuXi AppTec, MGI and BGI

103
103
article thumbnail

NIHR and TJBCM announce new funding initiative for novel brain tumour research

PharmaTimes

The condition is the ninth most common cancer in the UK and affects 12,300 people annually

article thumbnail

FDA clears BMS’ Breyanzi for follicular lymphoma

pharmaphorum

BMS gets another FDA approval for its CD19-directed CAR-T Breyanzi, this time as a third-line or later therapy for follicular lymphoma

FDA 107
article thumbnail

Reddit Rising: Increasing Visibility and Credibility for Discussions and Forums

Eversana Intouch

Reddit, on its way to becoming the third most visited global website, has formed a symbiotic relationship with Google, highlighting its growing digital importance. This presents a golden opportunity for pharma brands to utilize community-driven platforms like Reddit. Thanks to its recent Google partnership and exponential YoY growth in search appearances, Reddit is emerging as a key hub for genuine engagement and peer insights.

Pharma 59
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

AbbVie takes option on Gilgamesh CNS drugs in $2bn deal

pharmaphorum

AbbVie has agreed to pay $65 million on an option deal with start-up Gilgamesh Pharma, lining up rights to neuroplastogen compounds that can improve neuroplasticity - the ability of the brain to respond to changes. The two companies will work together on the development of a “next-generation” of psychiatric medicines, although – for now – the drugs themselves and the target indications are being kept under wraps. other than to say they include mood and anxiety disorders.

article thumbnail

GLP-1 receptor agonist sales expected to reach $125bn by 2033

Pharmaceutical Technology

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of Type 2 diabetes and obesity.

Sales 64
article thumbnail

AbbVie takes option on Gilgamesh psychedelics in $2bn deal

pharmaphorum

AbbVie joins a select group of big pharma groups working on psychedelic medicines, paying $65m on an option deal with Gilgamesh Pharma

Pharma 99
article thumbnail

Meeting the Challenges and Opportunities in Scholarly Communications with FAIR Data

Copyright Clearance Center

During a time of thorough transformation towards Open Access and, moreover, Open Science, the field of scholarly communications is facing new challenges. Some of the challenges are related to an aging and somewhat antiquated infrastructure, and others are related to new technologies and the evolving landscape of scientific dissemination, where the disclosure of data is becoming central to and an essential part of research and reproducibility.

52
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Uniquity Bio emerges with $300m for MSD immunology drug

pharmaphorum

New biotech startup Uniquity Bio emerges with $300m in funding from Blackstone and a clinical-stage asthma and COPD drug licensed from MSD

69
article thumbnail

Seven Amazing Activities at the LTEN Conference 2024

Quantified

The LTEN Conference is the premier gathering for professionals in the life sciences training field, and 2024 promises to be the best year yet. Whether you’re a seasoned educator, a training leader, or just stepping into the world of life sciences, this event offers tons of enriching experiences. Here are seven must-do activities to ensure a great experience at the conference. 1.

article thumbnail

Leading Sales Teams To Global Success: A Mother’s Day Special With Sydney Selby

Evolve Your Success

A Mother’s Day special! Join us as we sit down with Sydney Selby , the innovative Vice President of Sales, Marketing, and Medical Education at Renata Medical , during a week when we honor mothers and the gifts they bring into our lives. Sydney illuminates the often-invisible struggles within pediatric congenital heart disease treatment, revealing how Renata Medical’s Minima Renata stent system is revolutionizing care for the tiniest hearts.

article thumbnail

As Lilly surges, headwinds against its weight loss drugs are growing

PharmaVoice

After missing analysts’ earnings expectations for Mounjaro sales in the first quarter due to overwhelming demand, Lilly is also dealing with a legal loss and incoming pricing questions from lawmakers.

Sales 52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A